Release date- 30072019 - DUBLIN -
Alkermes plc (Nasdaq: ALKS) and Biogen Inc.
Alkermes (ALKS) and Biogen (BIIB) announced positive topline results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis, or RRMS, compared to TECFIDERA, or dimethyl fumarate.
Biopharmaceutical company
Alkermes plc (Nasdaq:ALKS) revealed on Wednesday the appointment of C.
Biopharmaceutical company
Alkermes plc (Nasdaq:ALKS) revealed on Monday the planned resignation of Jim Robinson with effect from 19 April 2019 for personal reasons.
The Food and Drug Administration has approved aripiprazole lauroxil (Aristada Initio) for the initiation of aripiprazole lauroxil (Aristada) for treating schizophrenia in adults, the drug's developer,
Alkermes, announced in a press release.
(NASDAQ: REPH) has closed its acquisition of assets from
Alkermes plc and its affiliates including worldwide rights to the IV/IM meloxicam pain drug and a contract manufacturing facility, royalty and formulation business, the company said.
Alkermes: Mark Namchuk, Ph.D., has been appointed senior vice president of Research, Pharmaceutical and Nonclinical Development.
[USPRwire, Tue Nov 25 2014] Global Markets Direct's, '
Alkermes Plc - Product Pipeline Review - 2014', provides an overview of the
Alkermes Plc's pharmaceutical research and development focus.
The research was supported by
Alkermes Inc., the manufacturer of that medication.